Navigation Links
Updated Phase 1 Data for Exelixis' XL184 Demonstrate Pharmacodynamic and Clinical Anti-Tumor Activity
Date:10/23/2007

al disease. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including GlaxoSmithKline, Bristol-Myers Squibb Company, Genentech, Wyeth Pharmaceuticals and Daiichi-Sankyo. For more information, please visit the company's web site at http://www.exelixis.com.

Forward-Looking Statements

This press release contains forward-looking statements, including without limitation statements related to the future development and potential efficacy of XL184 and the expected timing of the initiation of the phase 2 program of XL184. Words such as "believes," "will" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Exelixis' current expectations. Forward-looking statements involve risks and uncertainties. Exelixis' actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, the lengthy, costly and uncertain process of clinical testing of XL184 and Exelixis' other compounds, the potential failure of XL184 and Exelixis' other compounds to demonstrate safety and efficacy in clinical testing and risks related to Exelixis' dependence on and relationship with GlaxoSmithKline. These and other risk factors are discussed under "Risk Factors" and elsewhere in Exelixis' Quarterly Report on Form 10-Q for the quarter ended June 30, 2007 and its other filings with the Securities and Exchange Commission. Exelixis expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward- looking statements contained herein to reflect any change in Exelixis' expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.


'/>"/>
SOURCE Exelixis, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Infinity and MedImmune Present Updated Phase I Results of IPI-504 in GIST at ASCO Annual Meeting
2. Updated Study Results Reinforce Survival Benefit of Taxotere (Docetaxel) for Men with Advanced, Hormone-Resistant Prostate Cancer
3. Introgen Reports Updated Phase 2 Advexin Data Correlating Improved Survival, Tumor Responses and Predictive p53 Biomarker
4. Updated Overall Survival Data From Pivotal Herceptin Adjuvant Studies in HER2-Positive Breast Cancer
5. Vion Pharmaceuticals Presents Updated Clinical Data from a Phase II trial of Cloretazine (VNP40101M) in Patients with Relapsed or Refractory Small Cell Lung Cancer
6. Infinity and MedImmune Announce Updated Data On Ipi-504 to be Presented At ASCO
7. Avanir Pharmaceuticals Presents IEED Prevalence and Updated Zenvia Long-Term Safety Data at AAN Annual Meeting
8. Media Advisory: ACC Updated Schedule
9. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
10. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
11. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... October 24, 2014 Research ... addition of the "Global and Chinese Hemodialysis ... offering.      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ... 2014 is a professional and in-depth study on ... with a focus on the Chinese situation. ...
(Date:10/25/2014)... , Oct. 24, 2014  In 2008, two of ... quantities of multiple controlled substances, on a regular basis, ... reported that Dr. Gurney was practicing "all the time" ... one of his employees said that Dr. Gurney was ... of patients." Dr. Gurney,s behavior became increasingly ...
(Date:10/25/2014)... 24, 2014 In conjunction with DURECT Corporation,s ... results press release, you are invited to listen to ... the internet on Monday, November 3, 2014 at 4:30 ... A live audio webcast of the presentation will be ... and clicking "Investor Relations."  If you are unable to ...
Breaking Medicine Technology:Global and Chinese Hemodialysis Concentrates Industry Report 2014 2Global and Chinese Hemodialysis Concentrates Industry Report 2014 3Doctors That Harm: The Real Stories Insurance Companies Against Prop 46 Don't Want You To Know, Part 8 of Consumer Watchdog Campaign Series 2Doctors That Harm: The Real Stories Insurance Companies Against Prop 46 Don't Want You To Know, Part 8 of Consumer Watchdog Campaign Series 3DURECT Corporation Invites You to Join its Third Quarter 2014 Earnings Conference Call 2
... GLEN ALLEN, Va., Feb. 9, 2011 Rock Creek ... CIGX ) announced that on February 4 a ... Trademark Office ("PTO") for administering a pure form of ... be administered in a composition containing a therapeutically effective ...
... 2011 Cyberonics, Inc. (Nasdaq: CYBX ) today ... third quarter ended January 28, 2011 of its fiscal year ... regular market trading hours.  The company will conduct a conference ... 7:30 AM Central Time (8:30 AM Eastern Time). ...
Cached Medicine Technology:Rock Creek Pharmaceuticals Discloses Filing of Provisional Patent Application For Isolated Anatabine Isomer 2Rock Creek Pharmaceuticals Discloses Filing of Provisional Patent Application For Isolated Anatabine Isomer 3Rock Creek Pharmaceuticals Discloses Filing of Provisional Patent Application For Isolated Anatabine Isomer 4Cyberonics to Report Fiscal Year 2011 Third Quarter Results and Host Conference Call on March 2, 2011 2
(Date:10/25/2014)... Limbkeepers® announced today that they will ... Ed Begley Jr, airing 1st QTR 2015 via Discovery ... episode, Innovations will focus on Limbkeepers® non compression knit ... skin on arms, hands, and legs from abrasion, skin ... products, which help reduce injuries, allow for continued daily ...
(Date:10/25/2014)... Oct. 24, 2014 (HealthDay News) -- Researchers who ... their findings are cause for concern. The ... are raised for human consumption contribute to the ... according to background information from the study. ... sicken about 2 million people and kill about ...
(Date:10/25/2014)... 2014 (HealthDay News) -- October,s shorter, darker days can ... disorder, according to an expert. People affected ... overly tired, lack motivation and even have trouble getting ... to suicide, said Dr. Angelos Halaris, a professor in ... University Chicago Stitch School of Medicine. "Seasonal affective ...
(Date:10/22/2014)... Medical Solutions , the nation’s ... announce that our co-founder and CFO, Scott Anderson, ... 100 for 2014. Anderson was also named to ... in the staffing industry,” in 2013.     , Under ... staffing company in the U.S., was named a ...
(Date:10/22/2014)... -- The United States is now mandating that ... West Africa land at one of five airports ... virus. In a statement released Tuesday, Homeland ... of air passengers from Guinea, Liberia and Sierra ... airports -- New York City,s Kennedy International Airport, ...
Breaking Medicine News(10 mins):Health News:Upcoming Episode of Innovations with Ed Begley, Jr. to Feature Limbkeepers® 2Health News:Researchers Say Antibiotics in Fish a Health Concern 2Health News:Dark Days Here for Folks With Seasonal Depression 2Health News:Medical Solutions Co-Founder/CFO Scott Anderson Named to Staffing Industry Analysts’ 2014 Staffing 100 2Health News:Medical Solutions Co-Founder/CFO Scott Anderson Named to Staffing Industry Analysts’ 2014 Staffing 100 3Health News:Passengers From Ebola-Affected Countries Must Land at Designated U.S. Airports 2Health News:Passengers From Ebola-Affected Countries Must Land at Designated U.S. Airports 3
... CLEMENS, Mich., Nov. 25 Two more H1N1 vaccine clinics have ... Macomb County Health Department announced today. They are being offered at ... in Sterling Heights. , The Dec. 3 clinic will be held ... from 9 a.m. to 3 p.m. The thimerosol-free version of the ...
... Fla., Nov. 25 Daniel Touizer, CEO of Ci n ... guaranteed issue health insurance benefit programs, is concerned that the labor department,s recently ... job and unlikely to have health insurance. , "True unemployment ... highest rate in over 20 years," says Dani e ...
... and Spanish . Researchers from the ... ocular diseases that are very common today, such as age-related macular ... had never before been used for this purpose. Scientists from ... affected by one of these two pathologies, finding a greater amount ...
... available in French . Montreal, November 25, ... marketplace, thanks to a new partnership between Gestion Univalor, ... privately owned technology company based in Montreal. Univalor, ... its affiliated institutions, and CSI have announced the signature ...
... Discovery in fruit fly study may lead to new drugs ... -- Sphingadienes, natural lipid molecules found in soy, could become ... have found. , The findings are preliminary, but the ... soy seems to provide protection against colon cancer. , In ...
... experts offer waistline-friendly ways to enjoy festive feasting , WEDNESDAY, ... holiday smorgasbord from Thanksgiving to New Year,s, but are already ... come Jan. 1, help is at hand. , It,s possible, ... make it to 2010 weighing the same as you do ...
Cached Medicine News:Health News:Macomb County Health Department Schedules Two More H1N1 Flu Vaccine Clinics Dec. 3 and 5 2Health News:Cinergy Health Commentary on Health Care for the Unemployed 2Health News:Achieve early diagnosis of ocular pathologies such as keratitis and macular degeneration 2Health News:Univalor and Cognitive Sensing Inc. to commercialize 4 University of Montreal discoveries 2Health News:Natural Soy Component May Help Treat Colon Cancer 2Health News:Holiday Eating Without the Guilt -- or the Pounds 2Health News:Holiday Eating Without the Guilt -- or the Pounds 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: